Fig. 1: Landmark analysis in the German CLL Study Group CLL8 and CLL10 trials. | Leukemia

Fig. 1: Landmark analysis in the German CLL Study Group CLL8 and CLL10 trials.

From: Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Fig. 1: Landmark analysis in the German CLL Study Group CLL8 and CLL10 trials.The alternative text for this image may have been generated using AI.

PFS (A and C) and OS (B and D) at end of treatment by PB MRD and additional response status. Reprinted with permission from Kovacs G, Robrecht S, Fink AM, et al. Minimal residual assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two-phase III studies of the German CLL Study Group. J Clin Oncol. 2016;31:3758–3765. BM, bone marrow; CR, complete response; MRD-, minimal residual disease negative; MRD+, minimal residual disease positive; OS, overall survival; PFS, progression-free survival; PR, partial response.

Back to article page